|
1
|
Badar F, Meerza F, Khokhar RA, et al:
Characteristics of lung cancer patients - the Shaukat Khanum
Memorial experience. Asian Pac J Cancer Prev. 245–248. 2006.
|
|
2
|
Khuder SA: Effect of cigarette smoking on
major histological types of lung cancer: a meta-analysis. Lung
Cancer. 31:139–148. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gabrielson E: Worldwide trends in lung
cancer pathology. Respirology. 11:533–538. 2006. View Article : Google Scholar
|
|
4
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
5
|
Toh CK, Gao F, Lim WT, et al:
Never-smokers with lung cancer: epidemiologic evidence of a
distinct disease entity. J Clin Oncol. 24:2245–2251. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hsu LH, Chu NM, Liu CC, Tsai SY, You DL,
Ko JS, Lu MC and Feng AC: Sex-associated differences in non-small
cell lung cancer in the new era: is gender an independent
prognostic factor? Lung Cancer. 66:262–267. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kawaguchi T, Takada M, Kubo A, et al:
Gender, histology, and time of diagnosis are important factors for
prognosis: analysis of 1,499 never-smokers with advanced non-small
cell lung cancer in Japan. J Thorac Oncol. 5:1011–1017.
2010.PubMed/NCBI
|
|
8
|
Ding L, Getz G, Wheeler DA, et al: Somatic
mutations affect key pathways in lung adenocarcinoma. Nature.
455:1069–1075. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shigematsu H and Gazdar AF: Somatic
mutations of epidermal growth factor receptor signaling pathway in
lung cancers. Int J Cancer. 118:257–262. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sanders HR and Albitar M: Somatic
mutations of signaling genes in non-small-cell lung cancer. Cancer
Genet Cytogenet. 203:7–15. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Subramanian J and Govindan R: Molecular
genetics of lung cancer in people who have never smoked. Lancet
Oncol. 9:676–682. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sequist LV, Heist RS, Shaw AT, et al:
Implementing multiplexed genotyping of non-small-cell lung cancers
into routine clinical practice. Ann Oncol. 22:2616–2624. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mok TS, Wu YL, Thongprasert S, et al:
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N
Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rosell R, Moran T, Queralt C, et al:
Screening for epidermal growth factor receptor mutations in lung
cancer. N Engl J Med. 361:958–967. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Maemondo M, Inoue A, Kobayashi K, et al:
Gefitinib or chemotherapy for non-small-cell lung cancer with
mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhou C, Wu YL, Chen G, et al: Erlotinib
versus chemotherapy as first-line treatment for patients with
advanced EGFR mutation-positive non-small-cell lung cancer
(OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase
3 study. Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rosell R, Carcereny E, Gervais R, et al:
Erlotinib versus standard chemotherapy as first-line treatment for
European patients with advanced EGFR mutation-positive
non-small-cell lung cancer (EURTAC): a multicentre, open-label,
randomised phase 3 trial. Lancet Oncol. 13:239–246. 2012.
View Article : Google Scholar
|
|
18
|
Shigematsu H, Lin L, Takahashi T, et al:
Clinical and biological features associated with epidermal growth
factor receptor gene mutations in lung cancers. J Natl Cancer Inst.
97:339–346. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sugio K, Uramoto H, Ono K, Oyama T,
Hanagiri T, Sugaya M, Ichiki Y, So T, Nakata S, Morita M and
Yasumoto K: Mutations within the tyrosine kinase domain of EGFR
gene specifically occur in lung adenocarcinoma patients with a low
exposure of tobacco smoking. Br J Cancer. 94:896–903. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Boldrini L, Ali G, Gisfredi S, et al:
Epidermal growth factor receptor and K-RAS mutations in 411 lung
adenocarcinomas: A population-based prospective study. Oncol Rep.
22:683–691. 2009.
|
|
21
|
Toyooka S, Matsuo K, Shigematsu H, et al:
The impact of sex and smoking status on the mutational spectrum of
epidermal growth factor receptor gene in non small cell lung
cancer. Clin Cancer Res. 13:5763–5768. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Harichand-Herdt S and Ramalingam SS:
Gender-associated differences in lung cancer: clinical
characteristics and treatment outcomes in women. Semin Oncol.
36:572–580. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fan WC, Yu CJ, Tsai CM, et al: Different
efficacies of erlotinib and gefitinib in Taiwanese patients with
advanced non-small cell lung cancer: a retrospective multicenter
study. J Thorac Oncol. 6:148–155. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shukuya T, Takahashi T, Kaira R, et al:
Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung
cancer patients harboring epidermal growth factor receptor
mutations: a pooled analysis of published reports. Cancer Sci.
102:1032–1037. 2011. View Article : Google Scholar
|
|
25
|
Pao W and Ladanyi M: Epidermal growth
factor receptor mutation testing in lung cancer: searching for the
ideal method. Clin Cancer Res. 13:4954–4955. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lee CN, Yu MC, Bai KJ, Chang JH, Fang CL,
Hsu HL, Huang BS, Lu PC and Liu HE: NAT2 fast acetylator genotypes
are associated with an increased risk for lung cancer with wildtype
epidermal growth factor receptors in Taiwan. Lung Cancer. 64:9–12.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Salto-Tellez M, Tsao MS, Shih JY, et al:
Clinical and testing protocols for the analysis of epidermal growth
factor receptor mutations in East Asian patients with non-small
cell lung cancer: a combined clinical-molecular pathological
approach. J Thorac Oncol. 6:1663–1669. 2011. View Article : Google Scholar
|
|
28
|
Pirker R, Herth FJ, Kerr KM, et al:
Consensus for EGFR mutation testing in non-small cell lung cancer:
results from a European workshop. J Thorac Oncol. 5:1706–1713.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Beasley MB and Milton DT: ASCO provisional
clinical opinion: epidermal growth factor receptor mutation testing
in practice. J Oncol Pract. 7:202–204. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tokumo M, Toyooka S, Kiura K, et al: The
relationship between epidermal growth factor receptor mutations and
clinicopathologic features in non-small cell lung cancers. Clin
Cancer Res. 11:1167–1173. 2005.PubMed/NCBI
|
|
31
|
Tanaka T, Matsuoka M, Sutani A, et al:
Frequency of and variables associated with the EGFR mutation and
its subtypes. Int J Cancer. 126:651–655. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lee YJ, Shim HS, Kang YA, Hong SJ, Kim HK,
Kim H, Kim SK, Choi SH, Kim JH and Cho BC: Dose effect of cigarette
smoking on frequency and spectrum of epidermal growth factor
receptor gene mutations in Korean patients with non-small cell lung
cancer. J Cancer Res Clin Oncol. 136:1937–1944. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
D’Angelo SP, Pietanza MC, Johnson ML,
Riely GJ, Miller VA, Sima CS, Zakowski MF, Rusch VW, Ladanyi M and
Kris MG: Incidence of EGFR exon 19 deletions and L858R in tumor
specimens from men and cigarette smokers with lung adenocarcinomas.
J Clin Oncol. 29:2066–2070. 2011.PubMed/NCBI
|
|
34
|
Fukuoka M, Wu YL, Thongprasert S, et al:
Biomarker analyses and final overall survival results from a phase
III, randomized, open-label, first-line study of gefitinib versus
carboplatin/paclitaxel in clinically selected patients with
advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol.
29:2866–2874. 2011. View Article : Google Scholar
|
|
35
|
Jänne PA, Wang X, Socinski MA, Crawford J,
Stinchcombe TE, Gu L, Capelletti M, Edelman MJ, Villalona-Calero
MA, Kratzke R, Vokes EE and Miller VA: Randomized phase II trial of
erlotinib alone or with carboplatin and paclitaxel in patients who
were never or light former smokers with advanced lung
adenocarcinoma: CALGB 30406 trial. J Clin Oncol. 30:2063–2069.
2012.
|
|
36
|
Lee YJ, Cho BC, Jee SH, Moon JW, Kim SK,
Chang J, Chung KY, Park IK, Choi SH and Kim JH: Impact of
environmental tobacco smoke on the incidence of mutations in
epidermal growth factor receptor gene in never-smoker patients with
non-small-cell lung cancer. J Clin Oncol. 28:487–492. 2010.
View Article : Google Scholar : PubMed/NCBI
|
